Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck

Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck By ChinaBio Today CrowdStrike: The Bull Vs. Bear Perspective As The Stock Plummets Towards $100 A Share By C Jessen Citigroup Q4: Positioning For CCAR And Resumption Of Buybacks By IP Banking Research FEATURED: Get a year of Premium for $39 Make 2023 your best year yet! Seeking Alpha Premium empowers your investing with analysis of just about every stock and ETF. Join now at the incredibly low price of $39 for your first year and experience its immense value for yourself. Go Premium now » Long Ideas Nothing Ever Comes Easy For Lexicon, But Maybe Sotagliflozin Will Prevail In Heart Failure By Avisol Capital Partners Anheuser-Busch InBev: Buckle Up, The Flight Is About To Take Off By Fade The Market Meta Platforms: 3 Reasons To Buy By Cavenagh Research Sumitomo Mitsui Financial Group: A More Favorable Outlook By JP Research IBM: Undervalued With A Huge Hybrid Cloud Opportunity By Ben Alaimo More Long Ideas » Quick Picks & Lists Ford: A Short-Term Play By Z Kassotakis Which iBuyer Could Stage A Recovery In 2023, Opendoor Or Offerpad? By Leo Imasuen Week 52 MDA Breakout Stocks - December 2022: Short-Term Picks To Give You An Edge By JD Henning TransDigm: Starting To Lose Momentum By Gary Bourgeault Harmony Gold: An Earnings Recovery Story And A Bullish Technical Picture Shapes Up By Mike Zaccardi, CFA, CMT More Quick Picks & Lists » M&A Pan American Silver: An Upgrade To The Investment Thesis By Taylor Dart More M&A » Download the Seeking Alpha App! Like Stock Ideas? Try our other newsletters as well. This email was sent to you because you signed up to receive Stock Ideas. If you do not want to receive Stock Ideas emails, click here to unsubscribe. Sent by Seeking Alpha, 234 5th Ave, 5th floor, New York, NY 10001